Cancer Gene Therapy

Study Demonstrates Utility of Telomerase Promoter

Published in Gene Therapy Weekly, April 19th, 2001

Geron Corp. (GERN) announced the publication of a study that demonstrates the utility of the human telomerase promoter to drive the preferential expression of therapeutic genes in cancer cells.

The research, described in the April 4, 2001, issue of Gene Therapy, shows that the cloned promoter of the human telomerase reverse transcriptase (hTERT) gene can drive the selective expression of therapeutic genes in cancer cells in vitro and in vivo, while remaining inactive in normal somatic cells and tissues.

The research takes advantage of the fact that hTERT is expressed in essentially all human cancers, in which it functions to maintain the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry